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SUMMARY
Faithful chromosome segregation during mitosis de-
pends on the spindle assembly checkpoint (SAC),
which delays progression through mitosis until every
chromosome has stably attached to spindle microtu-
bules via the kinetochore. We show here that the
deubiquitinase USP9X strengthens the SAC by
antagonizing the turnover of the mitotic checkpoint
complex produced at unattached kinetochores.
USP9X thereby opposes activation of anaphase-pro-
moting complex/cyclosome (APC/C) and specifically
inhibits the mitotic degradation of SAC-controlled
APC/C substrates. We demonstrate that depletion
or loss of USP9X reduces the effectiveness of the
SAC, elevates chromosome segregation defects,
and enhances chromosomal instability (CIN). These
findings provide a rationale to explain why loss of
USP9X could be either pro- or anti-tumorigenic de-
pending on the existing level of CIN.
INTRODUCTION
During mitosis, the spindle assembly checkpoint (SAC) safe-
guards against aneuploidy by ensuring that each and every
chromosome is stably attached to microtubules before
anaphase is allowed to proceed (Lischetti and Nilsson, 2015;
Musacchio, 2015). Microtubules attach to each chromosome
via the kinetochore, a large multiprotein complex assembled
on centromeres (Pesenti et al., 2016). When kinetochores are
not attached to microtubules, they provide a platform for as-
sembly of the mitotic checkpoint complex (MCC), which inhibits
the anaphase-promoting complex/cyclosome (APC/C), an E3
ubiquitin ligase required to initiate mitotic exit (Alfieri et al.,
2016; Yamaguchi et al., 2016). The MCC is composed of the
APC/C co-activator Cdc20, bound to Mad2, BubR1, and
Bub3 (Chao et al., 2012). All of these components accumulate
at unattached kinetochores, and a key event in MCC assembly
is the ability of kinetochore-bound Mad1 to catalyze the conver-
sion of ‘‘open’’ Mad2 into ‘‘closed’’ Mad2 that can then stably
bind to Cdc20 (Luo et al., 2002; Sironi et al., 2002). The mature
MCC can diffuse throughout the cytoplasm and inhibit
APC/CCdc20 complexes to restrain progression through mitosis
(Izawa and Pines, 2015).
The SAC has key properties of being both exquisitely sensi-
tive and rapidly responsive. A single unattached kinetochore is
able to generate enough signal to prevent anaphase, and yet
this signal can still be silenced quickly after the last kinetochore
has attached to microtubules (Rieder et al., 1995). This rapid
silencing is a combination of fast signal termination at kineto-
chores, which shuts down new MCC production, and rapid
turnover of APC/C-bound MCC in the cytoplasm (Etemad
and Kops, 2016; Mansfeld et al., 2011). APC/C activity is
critical for this MCC turnover, and the presence of the APC15
subunit, in particular, allows APC/CMCC to adopt an open
conformation that is able to auto-ubiquitinate and degrade
MCC-bound Cdc20 (Alfieri et al., 2016; Foster and Morgan,
2012; Mansfeld et al., 2011; Uzunova et al., 2012). This MCC
turnover is also aided by a second pathway involving p31comet
and TRIP13, which extracts Mad2 out of the MCC complex
(Corbett, 2017).
The constant turnover of MCC is balanced during prometa-
phase by the continual synthesis of Cdc20 (Liang et al., 2012),
and therefore, as long as unattached kinetochores are present,
this can be incorporated into new MCC complexes to maintain
the SAC. The prediction is that a single unattached kinetochore
can generate enough new MCC to replenish the pool that is
turned over by the APC/C and p31comet/TRIP13, although how
such sensitivity is achieved remains unclear. One possibility is
that MCC turnover is restrained during mitosis by the action of
deubiquitinating enzymes (DUBs), and USP44 is one such
enzyme believed to antagonize Cdc20 ubiquitination to
strengthen the SAC (Stegmeier et al., 2007).
We show here that another DUB, USP9X, plays an important
role in the SAC. USP9X does not influence kinetochore signaling,
but rather it restrains Cdc20 ubiquitination, degradation, and
MCC turnover to maintain effective inhibition of the APC/C in
the presence of unattached kinetochores. This function is critical
for mitotic fidelity because loss of USP9X causes a reduction in
the efficiency of the SAC, an increased frequency of chromo-
some mis-segregations and the generation of chromosomal
instability (CIN). This could help explain why reduced USP9X
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expression has previously been linked to tumorigenesis in some
tissues (Pereira et al., 2016; Pe´rez-Mancera et al., 2012; Thanh
Nguyen et al., 2016).
RESULTS AND DISCUSSION
USP9X Is Required for an Efficient Mitotic Arrest
USP9X suppresses tumorigenesis in pancreatic ductal cancer,
and its expression is reduced in several other cancers (Pereira
et al., 2016; Pe´rez-Mancera et al., 2012; Thanh Nguyen et al.,
2016). USP9X has, however, also been proposed to promote tu-
mor cell survival by limiting the degradation of the anti-apoptotic
protein Mcl-1 (Schwickart et al., 2010). Because Mcl-1 is a major
determinant of cell fate in response to microtubule poisons (Har-
ley et al., 2010; Sloss et al., 2016; Wertz et al., 2011), we sought
to determine whether USP9X stabilized Mcl-1 during mitosis.
Control or USP9X-depleted human osteosarcoma U2OS cells
A
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B Figure 1. USP9X Catalytic Activity Is
Required for an Efficient SAC Arrest
(A) Western blot analysis with indicated antibodies
to show degradation of APC/C substrates during a
mitotic arrest induced by nocodazole (100 ng/mL)
in U2OS cells treated with control or USP9X
siRNAs. Nocodazole-arrested cells were collected
by wash-off and cultured for a further 2, 4, or 6 hr.
Asynchronous () cells were transfected with
indicated siRNA but not treated with nocodazole.
(B andC) Time-lapse analysis of duration ofmitosis
in U2OS cells treated with control or USP9X
siRNAs and arrested with nocodazole (B) or no-
codazole and different concentrations of reversine
(C), as indicated. For time-lapse analysis, 50 cells
were analyzed per condition, per experiment. All
graphs shown are representative of three inde-
pendent experiments.
(D) Western blot showing induction of siRNA-
resistant FLAG-USP9X wild-type (WT) and cata-
lytically dead (CD) protein after knockdown of
endogenous USP9X in HeLa FRT cells. Cells were
transfected with control or USP9X-1 siRNA for
24 hr, prior to addition of Dox for 48 hr to induce
expression of Flag-USP9X. Samples were blotted
with antibodies as indicated.
(E and F) Time-lapse analysis of duration of mitosis
in HeLa FRT-Flag USP9X (E) catalytically active
(WT) or (F) CD cells after knockdown of endoge-
nous USP9X and induction of Flag-USP9X as in
(D). Cells entered mitosis in the presence of
nocodazole (250 ng/mL) and reversine (0.35 mM)
and were imaged every 4 min. Fifty cells were
analyzed per condition.
See also Figure S1.
were arrested in mitosis with the microtu-
bule-destabilizing drug nocodazole for 2,
4, or 6 hr to examine the rate of degrada-
tion of Mcl-1 and key mitotic regulators.
Although USP9X depletion did not cause
an obvious change in Mcl-1 degradation
during mitosis, it did increase the loss of
other mitotic APC/C substrates, in partic-
ular cyclin A, but also cyclin B and NEK2A (Figure 1A). Therefore,
although USP9X does not have a specific role in controlling
Mcl-1 during mitosis, it does appear to stabilize other APC/C
substrates.
USP9X might function in mitosis to oppose the ubiquitination
of certain APC/C substrates directly, or it might control their sta-
bility indirectly through an effect on the SAC that restrains APC/C
activity. To test the possible role of USP9X in the SAC, we exam-
ined the ability of U2OS cells treated with nocodazole tomaintain
a prolonged mitotic arrest. We found that USP9X depletion
reduced the duration of the arrest and cells exited mitosis
despite the presence of the drug (Figure 1B). This effect was
also apparent when nocodazole was combined with different
doses of the Mps1 inhibitor reversine to reduce SAC strength
in a stepwise manner (Santaguida et al., 2011; Saurin et al.,
2011) (Figure 1C). The effect of USP9X depletion onmitotic arrest
was also observed with a second small interfering RNA (siRNA)
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targeting USP9X (Figure S1A). To investigate whether USP9X
catalytic activity is required to maintain the duration of mitotic
arrest, we generated HeLa-FRT cell lines stably expressing
doxycycline (Dox)-inducible and siRNA-resistant wild-type
(WT) USP9X or a catalytically dead (CD) form of USP9X in which
the critical cysteine residue in the active site is mutated (C1566A)
(Al-Hakim et al., 2008; Naik and Dixit, 2016) (Figure 1D).
Following depletion of endogenous USP9X, the normal duration
of mitotic arrest was restored by expression of WT-USP9X,
showing that the effect of USP9X depletion by siRNA is specific
and not an off-target effect (Figure 1E). Importantly expression of
CD-USP9X failed to restore the timing of mitotic arrest, demon-
strating that USP9X catalytic activity is required for this function
(Figure 1F). Similar results were observed in cell lines derived
from U2OS FRT cells in which WT- or CD-USP9X were ex-
pressed (Figures S1B–S1D). Collectively, these data demon-
strate that USP9X catalytic activity is required for cells to
maintain an efficient mitotic arrest in response to a microtubule
poison that engages and sustains the SAC.
USP9X Acts Downstream of Kinetochores to Maintain
the SAC
USP9X might help engage the SAC by acting through signaling
components at the kinetochore to generate a stronger check-
point signal. Alternatively, it might reinforce this checkpoint
signal by acting further downstream, for example, to limit sub-
strate ubiquitination by APC/C. To examine if USP9X affects
SAC signaling at kinetochores, we quantified the kinetochore
accumulation of SAC proteins in either control or USP9X-
depleted cells arrested in mitosis with nocodazole. We observed
no significant differences in the kinetochore levels of Mad1,
Mad2, or BubR1, in either nocodazole alone, or following a
30 min incubation with nocodazole and MG132 with different
doses of Mps1 inhibitor to modulate the kinetochore signal (Fig-
ures 2A–2F). Furthermore, baseline phosphorylation of theMELT
motifs on KNL1, a crucial Mps1 substrate needed for the SAC
(London et al., 2012; Shepperd et al., 2012; Yamagishi et al.,
2012), was also unaffected by USP9X knockdown (Figures
S2A and S2B). We conclude, therefore, that both Mps1 activity
and kinetochore SAC signaling are unaffected by USP9X deple-
tion. We confirmed that USP9X depletion affected the efficiency
of the checkpoint under these conditions by quantifying the time
to mitotic exit when different doses of Mps1 inhibitor were
applied to nocodazole-arrested cells. Figure 2G shows that
mitotic exit upon Mps1 inhibition was accelerated by USP9X
depletion even though kinetochore signaling is unaffected under
identical conditions (Figures 2A–2F).
USP9X has previously been reported to affect the levels of sur-
vivin, a key component of the chromosomal passenger complex
that controls the activity of aurora B kinase (Vong et al., 2005).
This could potentially affect SAC strength, because aurora B is
known to affect the SAC directly (Santaguida et al., 2011; Saurin
et al., 2011) and also indirectly by inhibiting kinetochore-microtu-
bule attachments (Lampson et al., 2004). However, a number of
lines of evidence suggest that this is not the case: first, we
observed no difference upon USP9X depletion in kinetochore/
centromere levels of aurora B or aurora B-pT232, a marker for
active aurora B (Yasui et al., 2004) (Figures S2C–S2F); second,
we observed no changes in the kinetochore levels of Mad2/
BubR1 (Figures 2C–2F), which are known to be reduced upon
aurora B inhibition (Ditchfield et al., 2003); and, third, we
observed no reduction in the levels of survivin following USP9X
knockdown (Figure S2G). We conclude therefore that the SAC
phenotype upon USP9X knockdown is unrelated to survivin or
aurora B activity.
Considering that USP9X depletion had no effect on the level of
signaling components at the kinetochore, we hypothesized that
USP9X might function instead to reinforce the SAC downstream
of kinetochores. To test this, we sought to use a condition in
which the SAC could be engaged in the absence of kinetochore
signaling: we chose to use YFP-Mad2 overexpression, because
this fusion protein can bind to MCC (presumably because of a
stable ‘‘closed’’ Mad2 conformation) and induce a prolonged
metaphase arrest due to constitutive SAC engagement in the
absence of kinetochore signaling (Tipton et al., 2011, 2013). As
expected, Dox-induced expression of YFP-Mad2 caused a
prolonged mitotic arrest, which was completely independent of
kinetochore signaling because it was unaffected by Mps1 inhibi-
tion with a high dose of either AZ 3146 (Hewitt et al., 2010) or
reversine (Figure 2H). Importantly, this arrest was still severely
attenuated by two separate siRNAs targeting USP9X (Figure 2H).
Furthermore, it was not due to differences in the level of YFP-
Mad2 overexpression or changes in the expression of other
components of the MCC, which all remained unaltered (Figures
2I and S2H). Collectively, these data strongly support the conclu-
sion that USP9X acts downstream of kinetochores to strengthen
a SAC-dependent arrest.
USP9XRestrains APC/CActivity toward SAC-Controlled
Substrates
Because USP9X is a DUB and the SAC signal relies on inhibition
of the APC/C ubiquitin ligase, USP9X might antagonize APC/
C-dependent ubiquitination to help maintain the SAC. USP9X
could potentially reinforce the SAC in two ways: it could limit
ubiquitination and degradation of certain key APC/C substrates,
therefore reducing the requirement for APC/C inhibition by the
MCC, or it could inhibit ubiquitination and turnover of the MCC
itself (Musacchio and Ciliberto, 2012), thus increasing the
strength of APC/C inhibition. To examine these possibilities,
we monitored the degradation of several APC/C substrates
using fluorescent reporters in live cells. We first examined the
degradation of cyclin B1, cyclin A, andNEK2A arrested inmitosis
by nocodazole because these APC/C substrates are all known to
be influenced by the strength of the SAC (Boekhout and Wolth-
uis, 2015; Brito and Rieder, 2006; Collin et al., 2013). In each
case, we monitored degradation in the presence or absence of
USP9X and/or reversine at 0.25 mM to partially inhibit Mps1.
When the SAC was weakened by reversine, the degradation of
cyclin B, cyclin A, and NEK2A was accelerated, as shown previ-
ously (Boekhout and Wolthuis, 2015; Collin et al., 2013) (Figures
3A–3C). Importantly, USP9X depletion was also sufficient to
accelerate the degradation of all of these substrates, particularly
in the absence of reversine when the rate of degradation was
under restraint by the SAC (Figures 3A–3C). These data demon-
strate that USP9X controls the rate of degradation of SAC-con-
trolled APC/C substrates during a mitotic arrest.
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We next sought to address whether USP9X could also affect
the degradation of APC/C substrates not controlled by the
SAC. We therefore monitored KIF18A, an APC/CCdc20 substrate
that is degraded early in anaphase following SAC silencing
(Sedgwick et al., 2013). As expected, KIF18A was not degraded
during a nocodazole arrest (Figure S3A), but it was degraded
shortly after mitotic exit following an unperturbed mitosis (Fig-
ure 3D). The rate of degradation of KIF18A during anaphase
was unaffected by USP9X depletion (Figure 3D), although we
could not exclude the possibility that USP9X activity is lost dur-
ing anaphase, when KIF18A is degraded. To circumvent this
issue, we next examined the degradation of Mcl-1, which is
A
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B Figure 2. USP9X Controls the SAC Down-
stream of Kinetochores
(A–F) Representative images (A, C, and E) and
quantification (B, D, and F) of Mad1 (A and B),
Mad2 (C and D), and BubR1 (E and F) localization
to kinetochores in nocodazole-arrested U2OS
cells treated with control or USP9X siRNAs. ACA
was used as a kinetochore marker. Cells were
treated with nocodazole for 4 hr, before DMSO or
reversine was added for 30 min, together with
proteasome inhibitor MG132 to prevent mitotic
exit. The graphs in (B), (D), and (F) show the mean
kinetochore intensities (±SD) relative to mock-
transfected, DMSO-treated cells, from three in-
dependent experiments with ten cells quantified
for each condition per experiment. ns, not signifi-
cant, unpaired Student’s t test. Scale bar, 10 mM.
(G) Quantification of the time to mitotic exit for
nocodazole-arrested U2OS cells treated with
control or USP9X siRNAs that were subsequently
treated with the indicated doses of reversine to
inhibit the kinetochore signal. The box-and-
whisker plots show the median (bar) together with
minima and maxima (whiskers). The data are from
three independent experiments with 50 cells
quantified for each condition per experiment.
***p < 0.001, unpaired Student’s t test.
(H) Time-lapse analysis of duration of mitotic arrest
in U2OS cells treated with control or USP9X
siRNAs and induced to express YFP-Mad2 for
16 hr prior to imaging. Cells were treated with re-
versine (1 mM) or AZ-3146 (5 mM) prior to imaging,
where indicated, to abolish the kinetochore SAC
signal. Fifty cells were analyzed per condition, and
the graph is representative of three experiments.
(I) Western blot analysis of U2OS cells, treated with
control or USP9X siRNA, and induced to express
YFP-Mad2 for 16 hr.
See also Figure S2.
not affected by MCC levels or the SAC
although its mitotic degradation is APC/
C-dependent (L.A.A., unpublished data).
Consistent with a lack of sensitivity to
the checkpoint, we found that Mcl-1
degradation during a mitotic arrest in
nocodazole was unaffected by Mps1
inhibition and/or USP9X depletion (Fig-
ure 3E), even though it is inhibited by
APC11 knockdown (Figure S3B). This confirms our earlier obser-
vation (Figure 1A) that USP9X is apparently not a DUB for Mcl-1
during mitosis, and it also suggests that it is not a general DUB
for all APC/C substrates.
Because Mcl-1 is an atypical APC/C substrate, we also tested
whether the mitotic degradation of a canonical APC/CCdc20
substrate, cyclin B, was affected by USP9X depletion. To pre-
vent any effects on MCC levels from indirectly affecting cyclin
B degradation, we monitored cyclin B levels in BubR1-depleted
cells treated with 1 mM reversine to abolish the SAC. Under these
conditions, cyclin B was degraded immediately following
nuclear envelope breakdown, and the rate of degradation was
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Figure 3. USP9X Restrains APC/C Activity toward SAC-Dependent Substrates
(A) Time-lapse analysis of endogenous Cyclin B-eYFP degradation in U2OS cells treated with control or USP9X siRNAs and arrested in nocodazole, with or
without reversine (0.25 mM), as indicated.
(B and C) Time-lapse analysis of cyclin A-Venus (B) or YFP-Nek2A (C) degradation in HeLa cells treated as in (A).
(D) Time-lapse analysis of Venus-Kif18A degradation during an unperturbed mitosis in HeLa cells treated with control or USP9X siRNAs. Cell images below the
graph indicate the point in anaphase when quantification started.
(E) Time-lapse analysis of YFP-Mcl-1 degradation in HeLa cells treated as in (A). Scale bar, 10 mM.
(legend continued on next page)
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unaffected by USP9X knockdown (Figures 3F and S3C). To
reduce the rate of cyclin B degradation, and to reveal potential
differences when USP9X is knocked down, we analyzed the
degradation of cyclin B-R42A, which carries a mutation within
the D-box and is degraded with much slower kinetics than the
WT protein (da Fonseca et al., 2011). We observed, however,
only a slight effect of USP9X depletion on the rate of cyclin
B-R42A degradation under these conditions (Figures 3G), in
contrast to the pronounced effect on the degradation of cyclin
B when the checkpoint was either fully or partially engaged
(Figure 3A). We therefore conclude that USP9X specifically pre-
serves the levels of MCC-dependent APC/C substrates during a
mitotic arrest, which is likely to be due to enhanced MCC-medi-
ated APC/C inhibition. BecauseUSP9X functions downstreamof
kinetochores, we next examined its role on MCC turnover.
USP9X Restricts APC/C-Mediated MCC Turnover
The MCC itself is an APC/C substrate that is constitutively ubiq-
uitinated and disassembled duringmitosis (Eytan et al., 2013; Ge
et al., 2009; Mansfeld et al., 2011; Reddy et al., 2007; Uzunova
et al., 2012; Zeng et al., 2010). Although unattached kineto-
chores are present to catalyze MCC production, the rate of
MCC assembly is thought to outstrip the rate of disassembly
and the APC/C remains inhibited. Upon full bipolar attachment
at metaphase, MCC production is shut down, and positive feed-
back drives rapid APC/C activation as APC/C degrades and
disassembles its own inhibitor (Musacchio and Ciliberto, 2012).
This ability of APC/C to release itself fromMCC-mediated inhibi-
tion is dependent on APC/C activity (Ge et al., 2009; Reddy et al.,
2007; Zeng et al., 2010) and on the APC15 subunit in particular,
which specifically drives APC/C-mediated MCC turnover (Alfieri
et al., 2016; Foster and Morgan, 2012; Mansfeld et al., 2011;
Uzunova et al., 2012). We therefore reasoned that if USP9X
antagonizes this process, then USP9X loss might reverse the
mitotic delay caused by reduced levels of key APC/C subunits.
We first depleted the RING finger (APC11) or cullin (APC2)
subunits that are critical for APC/C activity (Figures S4A and
S4B). Either of these depletions caused a delay in mitotic exit,
as expected, and this delay was indeed overcome by USP9X
co-depletion (Figures 4A and S4C). The primary effect of
APC11 or APC2 depletion therefore appears to be a strength-
ening of the SAC, and this is reversed by the loss of USP9X. In
agreement with this conclusion, APC2-depleted cells could be
induced to exit rapidly from a metaphase-arrested state by
Mps1 inhibition with reversine (Figure S4D). Therefore, enough
APC/C activity remains following APC2 depletion to promote
mitotic exit, as long as the SAC is weakened by either Mps1
inhibition or USP9X depletion. We presume that residual
APC/C activity following APC2 or APC11 depletion is due to
the incomplete penetrance of siRNA.
We next targeted the APC15 subunit, because this does not
affect APC/C activity per se but does inhibit APC/CMCC turnover
directly (Alfieri et al., 2016; Mansfeld et al., 2011; Uzunova et al.,
2012). APC15 knockdown also caused a delay in mitosis that
was abolished by co-depletion of USP9X (Figures 4B and
S4E). The delay in metaphase following APC15 knockdown is
due to a reduction in APC/CMCC disassembly, which interferes
with APC/CCdc20 reactivation and subsequent cyclin B degrada-
tion (Mansfeld et al., 2011; Uzunova et al., 2012). To test the pos-
sibility that USP9X depletion rescues APC/CMCC disassembly,
we monitored the interaction of MCC with APC/C under similar
conditions. Because of the requirement for large quantities of
cells in these experiments, we generated a constitutive USP9X
knockout cell line using CRISPR/Cas9 gene editing (Figure S4F),
and we verified that the knockout cells had a weakened SAC
response similar to that seen in cells depleted of USP9X by
siRNA (Figure S4G) and that this was rescued by expression of
WT- but not CD- USP9X (Figure S4H). Figures 4C and 4D
show that the release of MCC from the APC/C was delayed by
APC15 knockdown, as expected (Alfieri et al., 2016; Foster
and Morgan, 2012; Mansfeld et al., 2011; Uzunova et al.,
2012). However, this effect was diminished in USP9X knockout
cells. Notably, knockout of USP9X itself did not alter the levels
of APC15 protein (Figure S4I). We conclude, therefore, that
APC/C-mediated turnover of the MCC is indeed restrained
during mitosis by the catalytic activity of USP9X, which helps
preserve an efficient SAC arrest.
APC/CCdc20 disassemblesMCC by ubiquitinating and degrad-
ing MCC-bound Cdc20 (MCCCdc20) in a process that requires
APC15 (Alfieri et al., 2016; Foster and Morgan, 2012; Mansfeld
et al., 2011; Uzunova et al., 2012). We hypothesized that
USP9X might antagonize this ubiquitination to limit MCC turn-
over by APC/C. In agreement with this hypothesis, Cdc20 ubiq-
uitination was enhanced during a mitotic arrest in USP9X
knockout cells, even though steady-state levels of other MCC
components remained unaltered (Figures 4E, 4F, and S4J).
Endogenous Cdc20 is continuously synthesized during mitosis
to replace the pool that is degraded by APC/C (Liang et al.,
2012; Nilsson et al., 2008). We therefore monitored the levels
of ectopically expressed Venus-Cdc20 in nocodazole-arrested
cells, treated with control or USP9X siRNA. As expected,
Cdc20 was degraded during a nocodazole arrest (King et al.,
2007; Nilsson et al., 2008; Pan and Chen, 2004), but the rate of
Cdc20 degradation was enhanced following USP9X depletion
(Figure 4G). Importantly, this effect was in stark contrast to the
reduction in the rate of Cdc20 degradation when cells were
treated with reversine (Figure 4H), which is consistent with the
effect of Mad2 depletion shown previously by Nilsson et al.
(2008). Therefore, although weakening the kinetochore SAC
signal slows the rate of Cdc20 degradation due to reduced
(F) Time-lapse analysis of endogenous cyclin B-eYFP degradation in control or USP9X siRNA-treated U2OS cells without a functional SAC. The SAC was
abolished by BubR1 depletion and incubation with a high dose of reversine (1 mM).
(G) Time-lapse analysis of cerulean-cyclin B-R42A degradation in U2OS cells, treated as in (F). Doxycycline was added to express cyclin B-R42A for 44 hr prior to
imaging.
All graphs in (A)–(G) show the mean values (±SD) from three independent experiments with ten cells quantified for each condition per experiment. NEB, nuclear
envelope breakdown.
See also Figure S3.
Cell Reports 23, 852–865, April 17, 2018 857
AC
E F
D
G
H
B
Figure 4. USP9X Restricts APC/C-Mediated Cdc20 Degradation and MCC Turnover
(A) Time-lapse analysis of duration of mitotic arrest in U2OS cells treated with indicated siRNAs. The graph shows cumulative data from at least 50 cells from one
experiment, which is representative of three independent experiments.
(legend continued on next page)
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MCCCdc20 production, USP9X depletion actually enhances
Cdc20 degradation by promoting MCCCdc20 turnover. Collec-
tively, these data demonstrate that USP9X restrains Cdc20
ubiquitination and degradation to limit MCC turnover and pre-
serve a SAC arrest. We hypothesize that USP9X deubiquitinates
Cdc20 directly; however, we cannot rule out the possibility that
USP9X loss enhances Cdc20 ubiquitination and degradation
indirectly. Biochemical analysis with purified components will
be needed to resolve this issue.
USP9X Enhances SAC Efficiency to Protect against CIN
In the presence of many unattached kinetochores, the SAC
signal is strong and therefore, although USP9X depletion
reduces SAC efficiency in cells arrested in mitosis with nocoda-
zole, the arrest still persists for several hours (Figure 1B). We
hypothesized, however, that cells would rely more heavily on
USP9X to restrain MCC turnover and preserve the SAC in the
presence of just a few unattached kinetochores, when MCC
production is at its lowest. To test this idea, we used the micro-
tubule-stabilizing drug Taxol (paclitaxel) instead of nocodazole,
because Taxol is known to arrest cells with fewer unattached
kinetochores (Collin et al., 2013; Yang et al., 2009). We chose a
dose that would mimic the limited mitotic arrest caused by just
a single unattached kinetochore, estimated to be 2–3 hr in
HeLa cells (Dick and Gerlich, 2013). Figure 5A shows that under
these conditions, USP9X depletion reduced the Taxol-depen-
dent arrest from 154 ± 21 to 98.8 ± 10.8 min.
We reasoned that this premature mitotic slippage due to a
weakened SAC could lead to elevated levels of chromosome
mis-segregations and enhanced CIN. To test this hypothesis,
we generated multiple different early passage clones from
USP9X knockout or control parental cells (Figure S5). We moni-
tored chromosome segregation in these cells as they progressed
through an unperturbed mitosis and observed an increase in the
percentage of cells undergoing anaphase with misaligned or
lagging chromosomes following USP9X knockout (Figures 5B
and 5C). Chromosome counts of USP9X knockout or parental
cells that were either early passage or late passage showed
that although chromosome numbers in the control population
did not change appreciably over time, the chromosome numbers
in all five USP9X knockout clones became more heterogeneous
in the high passage cells, mainly because of an increased pro-
portion of cells containing fewer chromosomes (Figure 5D).
Thus, loss of USP9X results in chromosome segregation defects
and an inability to maintain their modal chromosomal number
over time. This study therefore provides clear evidence that
USP9X loss can lead to a CIN phenotype, presumably due to a
weakening of the SAC. Importantly, because the kinetochore
SAC signal is unaffected by USP9X loss, this also suggests
that kinetochore MCC production alone is not sufficient to
maintain chromosomal stability; rather, it must be aided by the
restraint of MCC turnover by USP9X.
The increased level of CINmight help explain why disruption of
USP9X cooperates with oncogenic K-Ras to drive pancreatic
ductal adenocarcinomas (PDAs) in mice and why low USP9X
expression correlates with poor survival following surgery and
an increased metastatic burden in advanced human PDA
(Pe´rez-Mancera et al., 2012). Furthermore, it may also explain
why USP9X levels are decreased in several other cancers (Per-
eira et al., 2016; Thanh Nguyen et al., 2016). It will be interesting
to determine whether USP9X levels are inversely correlated with
the level of numerical chromosomal aberrations in these tumors.
However, although USP9X depletion might contribute to
tumorigenesis by elevating CIN, there are many other routes to
CIN that do not require USP9X loss (Bastians, 2015). Our data
suggest that targeting USP9X that is retained in such tumors
may be an effective therapeutic approach because too much
CIN is detrimental to tumor cell survival (Andor et al., 2016; Birk-
bak et al., 2011; Janssen et al., 2009, 2011; Kops et al., 2004; Silk
et al., 2013; Weaver et al., 2007). In fact, recent evidence sug-
gests that tumors may reduce APC/C activity to limit CIN below
the threshold needed for viability; the rationale is that partial
APC/C inhibition extends the duration of metaphase and gives
time for cells to correct kinetochore attachment errors and clus-
ter centrosomes (Sansregret et al., 2017). In this report, we show
that USP9X depletion rescues the mitotic delays caused by
APC/C inhibition (Figures 4A, 4B, and S4A–S4C), which sug-
gests that USP9X inhibition may be an effective strategy to
elevate CIN and promote cell death in tumors that rely on
USP9X expression and/or reduced APC/C activity for survival.
Furthermore, reduced APC/C activity has also been shown to
promote chemo-resistance against anti-mitotic therapeutics
(Sansregret et al., 2017; Thu et al., 2018; Wild et al., 2016).
This is apparently due to the extension of mitosis, caused by
inefficient APCMCC turnover, which implies that USP9X inhibition
could re-sensitize tumors to these chemotherapeutics as well.
In summary, the data presented here show that USP9X antag-
onizes Cdc20 auto-ubiquitination and degradation to limit the
turnover of MCC complexes by APC/C. A similar role has been
reported previously for USP44 (Stegmeier et al., 2007), which
(B) Quantification of mitotic timing in HeLa cells uninduced () or induced (+) to express USP9X short hairpin RNAs (shRNAs) and treated with control or APC15
siRNAs. Mitotic timing indicates the time from mitotic cell rounding to anaphase. The graph shows the mean values (±SD) from three independent experiments
with 50 cells quantified for each condition per experiment. ***p < 0.001, unpaired Student’s t test.
(C and D)Western blot (C) and quantification (D) showing levels ofMCCproteins co-precipitated with APC3 in lysates from control or USP9X knockout HeLa cells,
with and without APC15 depletion, treated as indicated in panel inset. The graph in (D) shows the mean values (±SD) from at least two independent experiments
for nocodazole-arrested cells treated with reversine and MG132 for 50 min.
(E and F) Western blot (E) and quantification (F) showing levels of Cdc20 ubiquitination precipitated with Cdc20 antibody in lysates from control or USP9X
knockout HeLa cells, treated with nocodazole. The graph in (F) shows themean values (±SD) from three independent experiments. **p < 0.01, unpaired Student’s
t test.
(G and H) Time-lapse analysis of Venus-Cdc20 degradation in nocodazole-arrested HeLa cells treated with either control or USP9X siRNAs (G), or different
concentrations of reversine (H), as indicated. The graphs show the mean values (±SD) from three independent experiments with ten cells quantified for each
condition per experiment.
See also Figure S4.
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indicates that several different DUBs may reinforce the SAC by
limiting APC/C activity. How USP9X targets MCCCdc20 is
currently unclear, but it will be important to determine in future
whether it binds to any APC/C orMCC subunits, and in particular
whether there are any mechanistic links between USP9X and
APC15, the APC/C subunit that promotes Cdc20 ubiquitination
and MCC turnover (Alfieri et al., 2016; Foster and Morgan,
2012; Mansfeld et al., 2011; Uzunova et al., 2012).
Finally, it will also be important to determine whether USP9X is
regulated duringmitosis, because this may reveal new strategies
to modulate USP9X activity. If APC/C inhibition is a common
mechanism used by tumors to limit excessive CIN and generate
resistance against anti-mitotic drugs, as suggested (Sansregret
et al., 2017), then elevating APC/C activity in tumors by targeted
USP9X inhibition could represent a promising therapeutic
strategy.
EXPERIMENTAL PROCEDURES
Cell Lines, Vectors, and Cell Treatments
Cells were cultured in DMEM supplemented with 10% fetal bovine serum
(FBS) and 50 mg/mL penicillin/streptomycin. HeLa (OHIO) and U2OS
(HTB96) were obtained from Cell Services, Cancer Research UK London
Research Institute. To generate cell lines expressing Dox-inducible YFP-
Mcl-1, cyclin A-Venus, or YFP-Nek2A, HeLa Flp-In cells stably expressing
a TetR (Tighe et al., 2008) were co-transfected with pOG44 (Invitrogen) and
cDNAs cloned into pc5-LAP-YFP or pc5-LAP-Venus using FuGene HD
(Promega). Stable polyclonal cell lines were selected in media supplemented
with hygromycin (200 mg/mL). pcDNA5 vectors to generate Dox-inducible
Venus-Kif18A and Venus-Cdc20 cell lines (Sedgwick et al., 2013) were a
kind gift from Jakob Nilsson (University of Copenhagen). U2OS cells express-
ing Dox-inducible YFP-Mad2 or cyclin B-R42A-cerulean were generated by
transfecting U2OS-TR cells (Saurin et al., 2011) as above prior to selection
with Zeocin (100 mg/mL). Monoclonal cell lines were established by limiting
dilution and clones selected that gave the highest level of expression (YFP-
Mad2, clone 3; CycB-R42A-cerulean, clone 20). HeLa Flp-in and U2OS
Flp-in cells expressing Dox-inducible Flag-USP9X siRNA resistant to
USP9X-1 (J-006099-07; Dharmacon) were generated by transfection with
pCDNA5-FLAG-USP9X siRes-WT or siRes-CD (C1566A) (DU58547 and
DU58585; MRC Protein Phosphorylation and Ubiquitylation Unit, University
of Dundee) using FuGene HD. Stable polyclonal cell lines were selected in
media supplemented with hygromycin (200 mg/mL; Roche). Endogenously
tagged CycB-eYFP in U2OS cells were generated previously (Akopyan
et al., 2014).
HeLa cells expressing USP9X shRNA were generated by annealing syn-
thesized primers and subsequent ligation into pSUPERIOR vector (Oligoen-
gine). Resulting plasmids were transfected into Phoenix Ampho 239 cells,
using FuGene HD, to produce lentivirus expressing a Dox-inducible short
hairpin targeting USP9X (GAAAUAACUUCCUACCGAAttcaagagaUUCGGU
AGGAAGUUA-UUUC). Twenty-four hours after transfection, Phoenix
Ampho 293 cells were washed and placed into fresh medium. Forty-eight
hours after transfection, lentivirus-containing medium was collected and
filtered through a 0.45 mm filter before addition onto HeLa Flp-in cells. Cells
were infected with virus twice, in 24 hr intervals, before they were washed
and selected in puromycin-containing media for 3 days. Dox-inducible
knockdown of USP9X was then confirmed in polyclonal cells by western
blotting.
USP9X CRISPR-Cas9 knockout (KO) cell lines were generated according
to the method developed by Sanjana et al. (2014). Briefly, guide RNA se-
quences were designed against exon 2 using the online CRISPR design tool
(http://crispr.mit.edu). The complementary oligonucleotides for guide RNAs
(CACCGTGCATTTCCACATACTGACT-30 and 50-AAACAGTCAGTATGTGG
AAATGCAC-30) were annealed and cloned into lentiCRISPRv2 vector
(AddGene plasmid #52961). Resulting plasmids were co-transfected into
293T cells together with packaging plasmids pMD2 and vsvG, for lentivirus
production. Twenty-four hours after transfection, 293T cells were washed
and placed into fresh medium. Forty-eight hours after transfection, lenti-
virus-containing medium was collected and filtered through a 0.45 mm filter
before addition onto HeLa Flp-in and U2OS Flp-in cells. Cells were infected
with virus for 24 h before they were washed and selected in puromycin-con-
taining media for 3 days. KO of USP9X in polyclonal cells was confirmed by
western blotting, which showed the pool population displayed almost no
USP9X protein (Figure S4E). Clonal analysis demonstrated this residual
expression was due to the presence of a small population of cells containing
reduced USP9X expression. Considering the issues of working with single-
cell clones from an aneuploid cancer line, we performed the majority of
experiments with the pooled cell population. For analysis of chromosome
segregation defects and aneuploidy, single clones of parental HeLa-Flp-in
Cas9 and USP9X KO cells were isolated by limiting dilution.
The protocol for synchronizing cells in the period of mitotic arrest with noco-
dazole was described previously (Harley et al., 2010).
Antibodies and Reagents
The following antibodies were used for western blotting: APC11 (1/500,
ab57158), Mcl-1 (1/500, ab559027), Nek2A (1/500, ab610593), and p31comet
(1/1,000, ab97777) (all from Abcam); APC3 (1/1,000, 610454) and cyclin A
(1/1,000, 611269) (both from BD Biosciences); BubR1 (1/2,500, A300-386A;
Bethyl Laboratories); APC2 (1/1,000, 12301S; Cell Signaling Technology);
MPM2 (1/1,000, 05-368; Millipore); survivin (1/1,000, 2235; ProSci); USP9X
(55054-1; Proteintech); APC15 (1/1,000, sc-398488), Cdc20 (1/1,000,
sc-13162), and cyclin B (1/2,500, sc-752) (all from Santa Cruz Biotechnology);
actin (1/2,500, A2066), Bub3 (1/500, HPA003601), Flag (1/8,000, F3165), Mad2
(1/1,000, PA5-21594), and USP9X (1/1,000, WH0008239M1) (all from Sigma-
Aldrich).
The following primary antibodies were used for immunofluorescence: aurora
B (1/1,000, AIM-1, 611082; BD Biosciences); phospho-Thr232-aurora
B (1/2,000, 600-401-677; Rockland); BubR1 (1/1,000, A300-386A) and Mad2
(1/1,000, A300-301A; Bethyl Laboratories); Mad1 (1/1,000, MABE867;
Millipore); Cenp-C (1/1,000, PD-030; Caltag Medsystems); ACA/CREST
(1/1,000, FZ90C-CS1058; Europa Bioproducts); and KNL1-pMELT13/17
(1/2,000, Nijenhuis et al., 2014).
Secondary antibodies were Alexa Fluor 647 goat-anti-guinea pig, Alexa
Fluor 488 donkey anti-rabbit, and Alexa Fluor 568 goat anti-mouse (Invitrogen)
for immunofluorescence and anti-mouse/rabbit-HRP (Bio-Rad) for western
blotting (all at 1/1,000).
Figure 5. Loss of USP9X Induces Segregation Defects and Chromosomal Instability
(A) Average mitotic duration in Taxol-arrested (50 nM) U2OS cells treated with control or USP9X siRNAs. The graph shows the mean values (±SD) from two
independent experiments with 50 cells quantified for each condition. **p < 0.01, unpaired Student’s t test.
(B and C) Quantification (B) and representative images (C) of misaligned (arrows) and lagging (arrowheads) chromosomes in HeLa parental cells (HeLa7) and
USP9X knock out clones (KO12, KO13). The graph shows the mean values (±SD) from three independent experiments. At least 230 cells were analyzed per cell
line with >60 cells per experiment. DNA was visualized using SiR-DNA, and cells were imaged every 4 min. *p < 0.05 and **p < 0.01, unpaired Student’s t test.
Scale bar, 10 mM.
(D) Chromosome counts from metaphase spreads in parental (HeLa 6, 7, 8, 9) or USP9X knockout (KO12, KO13, KO14, KO15, KO17) HeLa clones at early (P7)
and late (P17) passage. The combined data for 150 cells from three independent experiments are shown; >40 cells were analyzed per experiment. Representative
images of metaphase spreads from parental and USP9X knockout cells at early and late passage are shown (right). Scale bar, 10 mM.
See also Figure S5.
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Dox (used at 1 mg/mL), thymidine (2 mM), paclitaxel, and reversine were
purchased from Sigma-Aldrich. MG132 (10 mM) was purchased from Tocris
Bioscience and AZ-3146 from Axon. Nocodazole (Calbiochem) was routinely
used at 250 ng/mL, unless otherwise stated. Karyomax Colcemid solution
was purchased from Thermo Fisher Scientific, and SiR-DNA was from
Tebu-Bio.
siRNA
To knockdown protein expression, cells were transfected with indicated siRNA
at a final concentration of 10 nM using Lipofectamine RNAiMAX Reagent
(Invitrogen), following the manufacturer’s instructions. ON-TARGET plus
siRNAs from Dharmacon were used unless otherwise stated. The following
siRNA duplexes were used in this study: USP9X-1: 50-ACACGAUGCUUUA
GAAUUU-30 (J-006099-07); USP9X-2: 50- GAAAUAACUUCCUACCGAA-30
(J-006099-09); USP9X-3: 50- GUACGACGAUGUAUUCUCA-30 (J-006099-
08); APC11-1: 50-UCUGCAGGAUGGCAUUUAA-30; APC11-2: 50-AAGAUUAA
GUGCUGGAACG-30 (Mansfeld et al., 2011; Eurofins-MWG); APC2-2:
50-GAUCGUAUCUACAAC AUGC-30 (J-003200-12); APC2-3: 50-GACAUCAU
CACCCUCUAU-30 (J-003200-11); APC2-4: 50-GAGAUGAUCCAGCGUC
UGU-30 (J-003200-10); APC15 50-CGAGAUGAAUGACUACAAU-30 (Izawa
and Pines, 2015); BubR1: AGAUCCUGGCUAACUGUUC; luciferase GL2:
50-CGUACGCGGAAUACUUCGA-30 (Eurofins-MWG); and GAPDH: 50-AUUC
CAUGGCACCGUCAAG-30 (Eurofins-MWG).
To obtain knockdowns of USP9X and APC15, cells were transfected for
72 hr and for knockdown of BubR1 for 48 hr. For knockdown of APC11 and
APC2, siRNA duplexes were pooled at an equimolar ratio and used at a final
concentration of 10 nM. Transfection was carried out for 48 hr.
Live-Cell Imaging
For time-lapse analysis of duration of unperturbed mitosis or mitotic arrest,
cells were plated into 24-well plates. The time in mitosis was measured as
the period from a cell rounding to flattening. All quantifications that were
compared directly were performed within the same experiment. Control or
USP9X knockdowns were carried out for 60–70 hr, and medium was replaced
with Leibovitz L-15 medium (Sigma-Aldrich), supplemented with 10% FBS,
2 mM L-glutamine, and 50 mg/mL penicillin/streptomycin. Cells were imaged
in a heated chamber (37C) using an EC Plan-Neofluar 103/0.3 objective on
a Zeiss Axiovert 200M microscope. Images were acquired using a C4742-
80-12AG camera (Hamamatsu) and mmanager software and were processed
using ImageJ Fiji.
For time-lapse analysis of duration of mitotic arrest in U2OS cells partially
depleted of APC11 or APC2 and co-depleted of USP9X, cells were transfected
with control or USP9X siRNA, followed by transfection with APC11 or APC2
siRNA 24 hr later. Cells were synchronized with thymidine and released into
fresh medium for 10 hr before being imaged as described above.
To study degradation of fluorescently labeled cyclin A, Nek2A, Mcl-1,
Kif18A, and Cdc20 by live-cell time-lapse analysis, cells were plated into
eight-well chamber slides (Ibidi). Control or USP9X knockdowns were
carried out for 60–70 hr, and medium was replaced with Leibovitz L-15
medium (Sigma-Aldrich), supplemented with 10% FBS, 2 mM L-glutamine,
50 mg/mL penicillin/streptomycin, and 1 mg/mL Dox. After 4 hr, nocodazole
(with DMSO or reversine) was added, and a further 4 hr later, cells were
imaged in a heated chamber (37C), using a DeltaVision Core or Elite micro-
scope system equipped with a 403/1.30 NA U Plan FLN objective using
softWoRx software (Applied Precision). Images were acquired with a
CoolSNAP HQ2 camera (Photometrics) and processed using softWoRx
software and ImageJ Fiji. Stacks of five images at 6 mm intervals were taken
at 4 min intervals for 16–18 hr. Maximum intensity projection of the fluores-
cent channels was performed using softWoRx software. Fluorescence
intensities are depicted as a percentage of the value at the time of mitotic
entry.
For live-cell imaging of endogenous Cyclin B-eYFP in USP9X and BubR1
co-depleted cells, cells were plated in eight-well chamber slides (Ibidi), trans-
fected with control or USP9X siRNA, followed by transfection with BubR1
siRNA. Twelve hours later, cells were synchronized with thymidine and
released into fresh medium for 4 hr, followed by addition of reversine (1 mM)
and imaging after 4 hr as described above.
For time-lapse analysis of cyclin B-R42A-cerulean degradation, cells were
transfected with control or USP9X siRNA, followed by transfection with
BubR1 siRNA. Twelve hours later, Dox was added and cells were arrested in
G1/S phase for 24 hr by addition of thymidine. Next, cells were released into
fresh medium for 4 hr, followed by addition of reversine (1 mM), and imaged
after 4 hr as described above.
To study the effect of Mps1 inhibition on mitotic duration following depletion
of APC2, cells were transfected with siRNA for 24 hr before being arrested with
thymidine (2mM) for 24 hr. Cells were then released into L-15medium contain-
ing SiR-DNA (100 nM) for 15 min before being cultured in L-15 for a further 6 hr
prior to the start of imaging. Reversine (1 mM) was added 4 hr later.
Immunofluorescence
For immunofluorescence analysis of localization of checkpoint proteins at
kinetochores, cells plated on 12 mm coverslips were pre-extracted with
0.1% Triton X-100 in PEM (100 mM PIPES [pH 6.8], 1 mM MgCl2 and 5 mM
EGTA) for 60 s before fixation with 4% paraformaldehyde in PBS for 15 min.
Coverslips were washed three times with PBS and blocked with 3% BSA in
PBS for 1 hr, incubated with primary antibodies overnight at 4C, washed
with PBS, and incubated with secondary antibodies and DAPI for 4 hr at
room temperature. Coverslips were then mounted using antifade (ProLong;
Molecular Probes). CREST/ACA and Cenp-C were used as kinetochores
markers, as indicated. All fixed images were acquired on a deconvolution
system (Deltavision Elite or Core), equipped with a 1003/1.40 NA U Plan
S Apochromat objective (Olympus) using softWoRx software. All displayed
images are maximum-intensity projections of deconvolved stacks. For quan-
tification of immunostaining, all images of similarly stained experiments were
acquired with identical illumination settings and analyzed using ImageJ. An
ImageJ macro was used to threshold and select all kinetochores, using the
DAPI and anti-kinetochore antibody channels. This was used to calculate
the relative mean kinetochore intensity of various proteins as shown previously
(Saurin et al., 2011).
For analysis of chromosome segregation defects, cells were plated onto
eight-well chamber slides (Ibidi) in DMEM supplemented with 10% FBS and
50 mg/mL penicillin/streptomycin. Four hours prior to imaging, cells were incu-
bated with 100 nM SiR-DNA in L-15 supplemented with 10% FBS, 2 mM
L-glutamine, and 50 mg/mL penicillin/streptomycin for 10 min before further
incubation in L-15 media without SiR-DNA. Cells were then imaged every
4 min using a Deltavision Core or Elite microscope as described for analysis
of fluorescent protein degradation.
Immunoprecipitation
Toquantify levelsofMCCproteinsonAPC/C,parental andUSP9XKOcellswere
transfectedwith control siRNAor APC15 siRNA for 34 hr, synchronized in thymi-
dine, and then released into fresh medium containing nocodazole for 12 hr. At
that time, mitotic cells were either treated with MG132 for 30 min or with
MG132 and reversine (0.5 mM) for 30 or 50 min. Cells were lysed in immunopre-
cipitation (IP) buffer (20mMTris [pH 7.5], 150mMNaCl, 10%glycerol, 1%Triton
X-100, 2 mM EDTA, 50 mM NaF, 5 mM b-glycerophosphate, 1 mM PMSF,
protease inhibitor cocktail), and a total of 0.5–1 mg of cleared extract was incu-
bated with 2 mg of APC3 antibody (sc-9972; Santa Cruz Biotechnology) or con-
trol IgG antibody (anti-sc35, 556363; BD Biosciences) for 2–4 hr and then with
protein G Dynabeads (Thermo Fisher Scientific) for 90 min at 4C on a rotating
wheel. Precipitates were washed three times for 5 min with lysis buffer followed
by incubation in SDS buffer for 4 min. Immunoblotting was performed using
standard protocol, except that anti-mouse light chain-specific HRP-conjugated
antibody was used as the secondary antibody (1/2,500, AP200P; Millipore).
To quantify Cdc20 ubiquitination, parental and USP9X KO cells were treated
with nocodazole for 4 hr. Mitotic cells were collected by mitotic wash-off, and
Cdc20 precipitation was performed using Cdc20 antibody (sc-13162; Santa
Cruz Biotechnology), following the same protocol, but extracts were incubated
with antibodies overnight at 4C. Immunoblotting was performed as above for
APC3 immunoprecipitations.
Karyotype Analysis of Metaphase Spreads
Cells were treated with 150 ng/mL Colcemid solution for 30 min in DMEM
supplemented with 10% FBS and 50 mg/mL penicillin/streptomycin. Cells
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were collected by trypsinization and resuspended in hypotonic buffer (20 mM
HEPES [pH 8.0], 1 mM MgCl2, 20 mM KCl, and 0.2 mM CaCl2) at room
temperature for 10 min. Samples were transferred to glass slides using a
cytospin, air-dried, fixed in methanol/acetic acid (3:1) at room temperature
for 10 min, and then washed twice in PBS. Immunofluorescence using
Cenp-C antibody and counterstaining with DAPI were carried out as
described above. Imaging was carried out using a Deltavision Core or Elite
microscope equipped with a 1003/1.40 NA U Plan S Apochromat objective
(Olympus) and a CoolSNAP HQ2 camera (Photometrics) using softWoRx
software. Stacks of 20 images at 0.2 mm intervals were taken. All images
are projections of deconvolved stacks.
Statistical Analysis
Statistical analysis was performed using GraphPad Prism 5 software. Differ-
ences between samples were assessed using unpaired Student’s t tests.
p values < 0.05 were considered to indicate statistical significance.
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